Comparative Pharmacology
Head-to-head clinical analysis: INDERIDE LA 160 50 versus ORVATEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDERIDE LA 160 50 versus ORVATEN.
INDERIDE LA 160/50 vs ORVATEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Propranolol: Non-selective beta-adrenergic receptor antagonist (blocks β1 and β2 receptors). Hydrochlorothiazide: Thiazide diuretic inhibiting Na+/Cl- cotransporter in distal convoluted tubule, reducing intravascular volume by increasing sodium and water excretion.
Orvaten is a purified form of tetrahydrobiopterin (BH4), a cofactor for aromatic amino acid hydroxylases including phenylalanine hydroxylase (PAH), tyrosine hydroxylase, and tryptophan hydroxylase. In patients with phenylketonuria (PKU), it enhances the activity of residual PAH, leading to increased metabolism of phenylalanine and reduced blood phenylalanine levels.
One capsule orally once daily. Each capsule contains propranolol hydrochloride 160 mg and hydrochlorothiazide 50 mg. Dosage should be individualized; typical maintenance dose is 1 capsule per day.
5 mg orally twice daily
None Documented
None Documented
Propranolol: 3-6 hours (parent drug), 8-12 hours (4-hydroxypropranolol active metabolite) with prolonged half-life in hepatic impairment; Hydrochlorothiazide: 6-15 hours, extended in renal impairment (creatinine clearance <30 mL/min).
Terminal half-life: 8-12 hours in healthy adults; prolonged to 20-30 hours in severe hepatic impairment necessitates dose adjustment.
Propranolol: primarily hepatic metabolism to inactive metabolites, <1% excreted unchanged in urine; Hydrochlorothiazide: 50-70% excreted unchanged in urine, remainder as metabolites via renal and biliary routes.
Renal: 60% unchanged; Biliary/fecal: 30% as metabolites; 10% exhaled as CO2.
Category C
Category C
Beta Blocker
Beta Blocker